ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 89 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q4 2020. The put-call ratio across all filers is 0.77 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $237,000 | +7.7% | 45,900 | -11.4% | 0.00% | – |
| Q2 2021 | $220,000 | +197.3% | 51,800 | +275.4% | 0.00% | – |
| Q1 2021 | $74,000 | -68.0% | 13,800 | +76.9% | 0.00% | – |
| Q4 2020 | $231,000 | +272.6% | 7,800 | 0.0% | 0.00% | – |
| Q3 2020 | $62,000 | -47.5% | 7,800 | -33.9% | 0.00% | – |
| Q2 2020 | $118,000 | +637.5% | 11,800 | +100.0% | 0.00% | – |
| Q1 2020 | $16,000 | +128.6% | 5,900 | 0.0% | 0.00% | – |
| Q4 2019 | $7,000 | – | 5,900 | +3370.6% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 170 | -91.1% | 0.00% | – |
| Q2 2019 | $8,000 | 0.0% | 1,900 | 0.0% | 0.00% | – |
| Q1 2019 | $8,000 | +60.0% | 1,900 | +100.0% | 0.00% | – |
| Q4 2018 | $5,000 | -61.5% | 950 | 0.0% | 0.00% | – |
| Q3 2018 | $13,000 | +18.2% | 950 | 0.0% | 0.00% | – |
| Q2 2018 | $11,000 | 0.0% | 950 | 0.0% | 0.00% | – |
| Q1 2018 | $11,000 | +83.3% | 950 | 0.0% | 0.00% | – |
| Q4 2017 | $6,000 | – | 950 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Matrix Capital Management Company, LP | 38,974,185 | $166,030,000 | 1.81% |
| Endurant Capital Management LP | 1,539,435 | $6,558,000 | 1.80% |
| NEA Management Company, LLC | 17,082,611 | $72,772,000 | 0.95% |
| PFM Health Sciences, LP | 3,627,900 | $15,455,000 | 0.48% |
| GSA CAPITAL PARTNERS LLP | 513,388 | $2,187,000 | 0.25% |
| Baker Brothers Advisors | 9,830,877 | $41,880,000 | 0.18% |
| Avoro Capital Advisors LLC | 2,024,400 | $8,624,000 | 0.15% |
| Vigilare Wealth Management | 54,250 | $231,000 | 0.14% |
| AlphaCentric Advisors LLC | 120,000 | $511,000 | 0.14% |
| Rock Springs Capital Management LP | 1,545,000 | $6,582,000 | 0.13% |